The D.C. Circuit’s recent decision in Vertex Pharmaceuticals Inc. v. HHS provides important guidance on the scope of the Anti-Kickback Statute (AKS) and the U.S. Department of Health and Human Services (HHS) Advisory Opinion process. The decision reinforces the broad reach of the AKS while also placing meaningful limits on how HHS evaluates and processes Advisory Opinion requests.
Vertex Pharmaceuticals v. HHS: The Case in Brief
Vertex developed Casgevy, a gene therapy for two hereditary blood disorders that requires a treatment course involving chemotherapy, which can adversely affect fertility. To address the concern that fertility risks could deter patients from choosing the treatment, Vertex created a program offering patients up to $70,000 in financial support for fertility services. After extending the program to privately insured patients, Vertex requested an Advisory Opinion from HHS on whether it could lawfully offer the same benefit to patients covered by federal healthcare programs.
HHS concluded that the program would violate both the Anti-Kickback Statute and the Beneficiary Inducement Statute. Vertex challenged the opinion in court, and the D.C. Circuit issued a mixed ruling with important implications for healthcare companies considering patient support programs or seeking HHS Advisory Opinions.
Key Takeaways from the D.C. Circuit’s Vertex Decision
The Anti-Kickback Statute Broadly Defines “Remuneration” and “Inducement”
The court held that “remuneration” and “induce” carry their plain, ordinary meanings under the Anti-Kickback Statute. Vertex argued those terms should be limited to corrupt or criminal transactions, but the panel rejected that reading. As Judge Rao wrote, “the AKS sweeps in actions that go beyond corrupt transactions.” For healthcare companies, this means patient support programs that offer financial value, even those designed to address legitimate clinical concerns, can trigger the statute if they are intended to induce patients to select a particular treatment.
HHS Must Adequately Explain Its Advisory Opinion Analysis
On the Beneficiary Inducement Statute, the court found HHS’s analysis inadequate. Vertex submitted substantial evidence that the program would qualify for the “Promotes Access to Care” exception, including research showing that fertility risks are a leading reason patients forgo treatment and that fertility services are often financially out of reach. HHS dismissed that evidence with a conclusory analysis, and the court called the agency’s failure to meaningfully engage with the exception “inconsistent with HHS’s statutory obligation and unreasonable.” Companies that submit well-supported Advisory Opinion requests are entitled to a reasoned agency response.
HHS Cannot Toll the 60-Day Advisory Opinion Deadline
The court held that HHS cannot toll the statutory 60-day deadline for issuing Advisory Opinions by requesting additional information. The court also rejected HHS regulations that delayed the start of the 60-day period until a request was “formally accepted,” holding that the statutory clock begins when the request is received. “HHS has no authority to circumvent this statutory deadline,” the court stated. This is a meaningful procedural win for companies that have experienced lengthy delays in the Advisory Opinion process.
What the Vertex Decision Means for Healthcare Companies
HHS Advisory Opinions remain one of the most effective tools available for healthcare companies to obtain regulatory clarity before launching a new program or arrangement. But as Vertex illustrates, the process requires a carefully structured request, well-developed supporting evidence, and a strategy for the possibility that HHS reaches an unfavorable conclusion.
How Frier Levitt Can Help
Frier Levitt’s healthcare regulatory attorneys routinely guide clients through the HHS Advisory Opinion process, from evaluating whether an Advisory Opinion is the right strategic move to developing the factual record and legal arguments that give a request the strongest possible foundation. If you have questions about the Anti-Kickback Statute, patient support programs, or whether an HHS Advisory Opinion may be appropriate for your organization, contact Frier Levitt to discuss your options.
Co-Managing Partner
